Abstract

Background and ObjectivesGlucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) are important regulators of insulin secretion, and their functional loss is an early characteristic of type 2 diabetes mellitus (T2DM). Pharmacological levels of GLP-1, but not GIP, can overcome this loss. GLP-1 and GIP exert their insulinotropic effects through their respective receptors expressed on pancreatic β-cells. Both the GLP-1 receptor (GLP-1R) and the GIP receptor (GIPR) are members of the secretin family of G protein-coupled receptors (GPCRs) and couple positively to adenylate cyclase. We compared the signalling properties of these two receptors to gain further insight into why GLP-1, but not GIP, remains insulinotropic in T2DM patients.MethodsGLP-1R and GIPR were transiently expressed in HEK-293 cells, and basal and ligand-induced cAMP production were investigated using a cAMP-responsive luciferase reporter gene assay. Arrestin3 (Arr3) recruitment to the two receptors was investigated using enzyme fragment complementation, confocal microscopy and fluorescence resonance energy transfer (FRET).ResultsGIPR displayed significantly higher (P<0.05) ligand-independent activity than GLP-1R. Arr3 displayed a robust translocation to agonist-stimulated GLP-1R but not to GIPR. These observations were confirmed in FRET experiments, in which GLP-1 stimulated the recruitment of both GPCR kinase 2 (GRK2) and Arr3 to GLP-1R. These interactions were not reversed upon agonist washout. In contrast, GIP did not stimulate recruitment of either GRK2 or Arr3 to its receptor. Interestingly, arrestin remained at the plasma membrane even after prolonged (30 min) stimulation with GLP-1. Although the GLP-1R/arrestin interaction could not be reversed by agonist washout, GLP-1R and arrestin did not co-internalise, suggesting that GLP-1R is a class A receptor with regard to arrestin binding.ConclusionsGIPR displays higher basal activity than GLP-1R but does not effectively recruit GRK2 or Arr3.

Highlights

  • Glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) are incretin hormones that function primarily to enhance glucose-stimulated insulin secretion [1,2]

  • Arr3 displayed a robust translocation to agonist-stimulated GLP-1 receptor (GLP-1R) but not to GIP receptor (GIPR). These observations were confirmed in fluorescence resonance energy transfer (FRET) experiments, in which GLP-1 stimulated the recruitment of both G protein-coupled receptors (GPCRs) kinase 2 (GRK2) and Arr3 to GLP-1R

  • GLP-1 and GIP stimulated cyclic adenosine monophosphate (cAMP)-responsive luciferase activity in a dose-dependent manner in HEK-293 cells transfected with Cre-luc and either wild-type GLP-1R or GIPR

Read more

Summary

Introduction

Glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) are incretin hormones that function primarily to enhance glucose-stimulated insulin secretion [1,2]. Their functional impairment is an early characteristic of type 2 diabetes mellitus (T2DM) [3]. GIP is involved in adipocyte metabolism and bone formation and may have neuroprotective and neurotrophic effects [7,8,9] Together, these actions make GLP-1R and GIPR exciting targets for the treatment of diabetes and obesity and potentially of ischemic heart disease and neurodegenerative diseases, such as Alzheimer’s disease and Parkinson’s disease. Glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) are important regulators of insulin secretion, and their functional loss is an early characteristic of type 2 diabetes mellitus (T2DM). We compared the signalling properties of these two receptors to gain further insight into why GLP-1, but not GIP, remains insulinotropic in T2DM patients

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call